Development of prognostic models for survival and care status in sporadic Creutzfeldt-Jakob disease.
Creutzfeldt-Jakob
dementia
prion
prognosis
survival model
Journal
Brain communications
ISSN: 2632-1297
Titre abrégé: Brain Commun
Pays: England
ID NLM: 101755125
Informations de publication
Date de publication:
2022
2022
Historique:
received:
08
02
2022
revised:
04
04
2022
accepted:
01
08
2022
entrez:
17
8
2022
pubmed:
18
8
2022
medline:
18
8
2022
Statut:
epublish
Résumé
Sporadic Creutzfeldt-Jakob disease, the most common human prion disease, typically presents as a rapidly progressive dementia and has a highly variable prognosis. Despite this heterogeneity, clinicians need to give timely advice on likely prognosis and care needs. No prognostic models have been developed that predict survival or time to increased care status from the point of diagnosis. We aimed to develop clinically useful prognostic models with data from a large prospective observational cohort study. Five hundred and thirty-seven patients were visited by mobile teams of doctors and nurses from the National Health Service National Prion Clinic within 5 days of notification of a suspected diagnosis of sporadic Creutzfeldt-Jakob disease, enrolled to the study between October 2008 and March 2020, and followed up until November 2020. Prediction of survival over 10-, 30- and 100-day periods was the main outcome. Escalation of care status over the same time periods was a secondary outcome for a subsample of 113 patients with low care status at initial assessment. Two hundred and eighty (52.1%) patients were female and the median age was 67.2 (interquartile range 10.5) years. Median survival from initial assessment was 24 days (range 0-1633); 414 patients died within 100 days (77%). Ten variables were included in the final prediction models: sex; days since symptom onset; baseline care status;
Identifiants
pubmed: 35974795
doi: 10.1093/braincomms/fcac201
pii: fcac201
pmc: PMC9374480
doi:
Types de publication
Journal Article
Langues
eng
Pagination
fcac201Subventions
Organisme : Medical Research Council
ID : G0400713
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00024/9
Pays : United Kingdom
Organisme : NIA NIH HHS
ID : RF1 AG055654
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain.
Références
Lancet. 1999 Jul 24;354(9175):317-23
pubmed: 10440324
J Neurol Neurosurg Psychiatry. 2022 Apr;93(4):404-412
pubmed: 35022318
BMJ. 1998 Feb 21;316(7131):577-82
pubmed: 9518907
J Neurol Neurosurg Psychiatry. 2021 Apr;92(4):349-356
pubmed: 33380492
Alzheimers Dement. 2017 Jun;13(6):710-719
pubmed: 27870938
Hum Mol Genet. 2014 Oct 1;23(19):5102-8
pubmed: 24833721
Mol Psychiatry. 2021 Oct;26(10):5955-5966
pubmed: 33674752
Lancet Neurol. 2018 May;17(5):423-433
pubmed: 29598923
Ann Clin Transl Neurol. 2020 Sep;7(9):1535-1545
pubmed: 33314770
Lancet Neurol. 2009 Apr;8(4):334-44
pubmed: 19278902
J Psychiatr Res. 1975 Nov;12(3):189-98
pubmed: 1202204
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Brain. 2004 Oct;127(Pt 10):2348-59
pubmed: 15361416
Arch Neurol. 2009 Feb;66(2):208-15
pubmed: 19204157
Neurology. 2020 Feb 4;94(5):e538-e548
pubmed: 31843808
Ann Intern Med. 2015 Jan 6;162(1):55-63
pubmed: 25560714
J Neurol Neurosurg Psychiatry. 2016 Oct;87(10):1061-7
pubmed: 27413165
Brain. 2013 Apr;136(Pt 4):1116-27
pubmed: 23550114
Nature. 2016 Nov 09;539(7628):217-226
pubmed: 27830781
JAMA Neurol. 2019 Aug 01;76(8):969-977
pubmed: 31058916
Lancet Neurol. 2022 Apr;21(4):342-354
pubmed: 35305340
Methods Mol Biol. 2017;1658:311-346
pubmed: 28861799
Eur J Neurol. 2021 Sep;28(9):2901-2906
pubmed: 34060706
Handb Clin Neurol. 2018;153:399-408
pubmed: 29887147
Int Psychogeriatr. 2019 Aug;31(8):1181-1190
pubmed: 30353798
Lancet Neurol. 2021 Mar;20(3):235-246
pubmed: 33609480
Alzheimers Dement. 2020 Oct;16(10):1438-1447
pubmed: 32614136
Ann Neurol. 2021 Mar;89(3):560-572
pubmed: 33274461